We’re back! Sara and I had a pretty rough summer with actual work, so we didn’t have much time to record anything. We chose a recent study on how outdoor time affects myopia progression.
We discuss the points brought up in the book But I Don't Sell by Steve Vargo, OD, MBA. We strongly recommend reading this book if you work in a private practice setting whether you own a practice or not.
We go over an interesting case that led to a top-notch review article. The diagnosis of limbal stem cell deficiency in The Ocular Surface. It has a great summary/table on the proper diagnosis of LSCD.
In this episode, we discuss the article Associations Between Peripapillary Retinal Nerve Fiber Layer and Choroidal Thickness With the Development and Progression of Diabetic Retinopathy in the journal Investigative Ophthalmology and Visual Science.
Everything you need to know about Ocular Surface Squamous Neoplasia. In this episode, Sara shows off an OSSN lesion that she saw in residency. We plan on posting it to the website, so check out whatthefundus.com for that.
The gauntlet has been thrown. The blue-light-hazard vs. blue-light-hype in the February issue of Opthalmology basically calls blue-light-blocking IOLs pure snake oil. We break down their arguments.
We talk about the paper Goji Berry Intake Increases Macular Pigment Optical Density in Healthy Adults: A Randomized Pilot Trial which talks about the benefits that a steady diet of goji berries can have on macular pigment density.
Treating MGD is basically all we do now, right? In this episode, we discuss Efficacy and Safety of Lipiflow for Treating Meibomian Gland Dysfunction from the journal Graefe's Archive for Clinical and Experimental Ophthalmology.
A recent paper published in JAMA Ophthalmology discusses our potentially overblown fear of prescribing oral CAIs to lower IOP.
Problems with pericytes have been shown to be a major cause of the issues related to diabetes. A recent study in the journal of the PNAS shows that an issue with how they regulate calcium ion transfer may play a role in glaucomatous damage. Get ready for some basic science information!
We're back after a brief hiatus to talk about a paper published in Contact Lens and Anterior Eye about the incidence of positive corneal ulcer cultures.
Sorry, this is a few days late this week, but things have been a little crazy. Sara and I talk about a study discussing red light therapy to slow myopia progression. I also talk about my initial experience with Vuity. -- MM
Sara and I discuss the relatively quiet launch of Rayban Stories glasses. -- MM
Sara and I discuss the paper High-Fat Diet Induces Inflammation of Meibomian Gland. There are some problems with it, but the science is pretty great. -- MM
Dr. Toomey and I talk about a recently released drug called Tyrvaya from Oyster Point Pharmaceuticals. In this podcast we reference two articles. Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease: the ONSET-2 Phase 3, Randomized Trial and Randomized, Controlled, Double-Masked, Multicenter, Pilot Study Evaluating Safety and Efficacy of Intranasal Neurostimulation for Dry Eye Disease -- MM
This week Sara and I discuss the paper Lower Cognitive Function in Patients With Functionally and Structurally Severe Glaucoma: The LIGHT Study from the Journal of Glaucoma. -- MM
Today we cover a recent study that discusses treatment of central serous chorioretinopathy. Thanks for listening. If you have any suggestions for topics you want us to cover, please reach out to Michael on Twitter @mikeeyes.
The link to the article regarding Parkinsons Disease and the eye can be found here.
This week, Sara and Michael talk about the newly approved drop to treat the symptoms of presbyopia called Vuity. You can get samples by visiting their website.
(One correction: I referred to Dr. David Sinclair's excellent book Lifespan as "Ageless". I apologize for the the error -- MM)
Dr. Toomey discusses her experience with doing genetic testing on patients in her time at Bascom Palmer. Here's a link to the lab that does IRD testing that I incorrectly referred to as Invictus. It is Invitae. To learn more about treating IRD, head to Spark Therapeutics for more information.
Welcome to the inaugural What the Fundus podcast. In this episode we talk about a new study involving Xiidra. For more information or for more eye-related information, check out our website. The study we talk about in this episode can be found here.